44 citations
,
May 1998 in “PubMed” The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.
3 citations
,
July 2015 in “Australasian Journal of Dermatology” A man developed an allergic skin reaction to a rosacea treatment and improved after stopping the medication and receiving allergy-specific care.
12 citations
,
September 2014 in “Bone” A vitamin D receptor mutation causes rickets and affects immune responses.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
February 1996 in “Clinical Pharmacology & Therapeutics” MK-386 reduces sebum DHT levels.
1 citations
,
October 2017 in “Food Additives & Contaminants: Part A” A new minoxidil-like substance, triaminodil, was found in an illegal hair growth supplement.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
6 citations
,
December 2019 in “Dermatologic Therapy” Oral dutasteride improves hair growth, reduces hair loss, and is safe for most patients.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
1 citations
,
January 2014 in “Side effects of drugs annual” Antihelminthic drugs treat worm infections but face challenges like low treatment coverage and potential drug resistance, with various side effects reported for different drugs.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
15 citations
,
October 2014 in “Hormone Molecular Biology and Clinical Investigation” Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
2 citations
,
August 2023 in “Molecules” SH-340 may improve skin barrier and help treat atopic dermatitis.
Combining α-blockers and Finasteride is useful for treating small prostate enlargement.
9 citations
,
January 2018 in “Acta Clinica Croatica” Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
1 citations
,
August 2025 in “Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine” BMI should be considered in future research on dutasteride's effects on fertility.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
November 2004 in “Oncology Times” Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
7 citations
,
April 2006 in “Experimental Neurology” Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.
January 2025 in “Dusunen Adam The Journal of Psychiatry and Neurological Sciences” April 2011 in “Reactions Weekly” June 2011 in “British Journal of Urology” Regulatory challenges make developing combination therapies in urology difficult and costly.
13 citations
,
November 2010 in “Experimental Dermatology” Vitamin C derivative reduces hair loss-related protein in cells.
4 citations
,
September 2010 in “Medical Hypotheses”
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.